Hong Kong Stock Movement | DUALITYBIO-B (09606) Rises Over 5% Intraday as Company's First ADC Expected to Submit Listing Application This Year

Stock News

Oct 13, 2025

DUALITYBIO-B (09606) surged over 5% during trading, and as of press time, the stock was up 4.68% to HK$308.4, with trading volume reaching HK$104 million.

On the news front, according to the latest report "2025-2030 China Antibody Drug Conjugate (ADC) Industry Research and Market Investment Decision Report" released by China Research and Intelligence, China's ADC market size is expected to exceed 100 billion yuan in the next five years, becoming the world's second-largest ADC market.

DUALITYBIO-B's DB-1419 (B7-H3/PD-L1 bispecific ADC) has demonstrated excellent efficacy in solid tumor clinical trials, marking a technological breakthrough for Chinese companies in the bispecific ADC field. A research report noted that according to Frost & Sullivan, the global ADC market size was approximately $10.4 billion in 2023, and is expected to reach $115.1 billion by 2032.

According to DUALITYBIO-B's announcement, the company expects to submit marketing applications for DB-1303 (HER2 ADC) for endometrial cancer in the United States and for breast cancer in China in 2025. The company's DB-1311 (B7-H3 ADC) has shown potential best-in-class capabilities in prostate cancer, while DB-1310 (HER3 ADC) is expected to catch up from behind. DB-1305 (TROP2 ADC) and combination exploration with bispecific antibodies are leading globally, with autoimmune and bispecific ADCs continuously driving next-generation ADC frontier exploration.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1113503517"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113503517\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113503517?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 10:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113503517","market":"fut","top_or_hot":-1,"title":"Hong Kong Stock Movement | DUALITYBIO-B (09606) Rises Over 5% Intraday as Company's First ADC Expected to Submit Listing Application This Year","media":"Stock News","content":"<p>DUALITYBIO-B (09606) surged over 5% during trading, and as of press time, the stock was up 4.68% to HK$308.4, with trading volume reaching HK$104 million.</p>\n<p>On the news front, according to the latest report \"2025-2030 China Antibody Drug Conjugate (ADC) Industry Research and Market Investment Decision Report\" released by China Research and Intelligence, China's ADC market size is expected to exceed 100 billion yuan in the next five years, becoming the world's second-largest ADC market.</p>\n<p>DUALITYBIO-B's DB-1419 (B7-H3/PD-L1 bispecific ADC) has demonstrated excellent efficacy in solid tumor clinical trials, marking a technological breakthrough for Chinese companies in the bispecific ADC field. A research report noted that according to Frost & Sullivan, the global ADC market size was approximately $10.4 billion in 2023, and is expected to reach $115.1 billion by 2032.</p>\n<p>According to DUALITYBIO-B's announcement, the company expects to submit marketing applications for DB-1303 (HER2 ADC) for endometrial cancer in the United States and for breast cancer in China in 2025. The company's DB-1311 (B7-H3 ADC) has shown potential best-in-class capabilities in prostate cancer, while DB-1310 (HER3 ADC) is expected to catch up from behind. DB-1305 (TROP2 ADC) and combination exploration with bispecific antibodies are leading globally, with autoimmune and bispecific ADCs continuously driving next-generation ADC frontier exploration.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movement | DUALITYBIO-B (09606) Rises Over 5% Intraday as Company's First ADC Expected to Submit Listing Application This Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movement | DUALITYBIO-B (09606) Rises Over 5% Intraday as Company's First ADC Expected to Submit Listing Application This Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-13 10:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>DUALITYBIO-B (09606) surged over 5% during trading, and as of press time, the stock was up 4.68% to HK$308.4, with trading volume reaching HK$104 million.</p>\n<p>On the news front, according to the latest report \"2025-2030 China Antibody Drug Conjugate (ADC) Industry Research and Market Investment Decision Report\" released by China Research and Intelligence, China's ADC market size is expected to exceed 100 billion yuan in the next five years, becoming the world's second-largest ADC market.</p>\n<p>DUALITYBIO-B's DB-1419 (B7-H3/PD-L1 bispecific ADC) has demonstrated excellent efficacy in solid tumor clinical trials, marking a technological breakthrough for Chinese companies in the bispecific ADC field. A research report noted that according to Frost & Sullivan, the global ADC market size was approximately $10.4 billion in 2023, and is expected to reach $115.1 billion by 2032.</p>\n<p>According to DUALITYBIO-B's announcement, the company expects to submit marketing applications for DB-1303 (HER2 ADC) for endometrial cancer in the United States and for breast cancer in China in 2025. The company's DB-1311 (B7-H3 ADC) has shown potential best-in-class capabilities in prostate cancer, while DB-1310 (HER3 ADC) is expected to catch up from behind. DB-1305 (TROP2 ADC) and combination exploration with bispecific antibodies are leading globally, with autoimmune and bispecific ADCs continuously driving next-generation ADC frontier exploration.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADC","symbol_name":"艾格里房产","start_time":0,"source_url":"","article_id":"1113503517","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113503517","pubTimestamp":1760323099,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"DUALITYBIO-B (09606) surged over 5% during trading, and as of press time, the stock was up 4.68% to HK$308.4, with trading volume reaching HK$104 million. On the news front, according to the latest...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADC":"艾格里房产","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","YANG":"三倍做空富时中国ETF-Direxion","09606":"映恩生物-B","BK4231":"零售房地产信托","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","BK4614":"Manus概念股","BK4080":"零售业房地产投资信托","07226":"南方两倍做多恒科","HSCEI":"国企指数","BK1161":"生物科技","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元"},"translate_title":"港股动向|DUALITYBIO-B(09606)盘中涨超5%公司首个ADC有望年内递交上市申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1,"YANG":1,"09606":1,"HSCEI":1,"07226":1},"content_text":"DUALITYBIO-B (09606) surged over 5% during trading, and as of press time, the stock was up 4.68% to HK$308.4, with trading volume reaching HK$104 million.\nOn the news front, according to the latest report \"2025-2030 China Antibody Drug Conjugate (ADC) Industry Research and Market Investment Decision Report\" released by China Research and Intelligence, China's ADC market size is expected to exceed 100 billion yuan in the next five years, becoming the world's second-largest ADC market.\nDUALITYBIO-B's DB-1419 (B7-H3/PD-L1 bispecific ADC) has demonstrated excellent efficacy in solid tumor clinical trials, marking a technological breakthrough for Chinese companies in the bispecific ADC field. A research report noted that according to Frost & Sullivan, the global ADC market size was approximately $10.4 billion in 2023, and is expected to reach $115.1 billion by 2032.\nAccording to DUALITYBIO-B's announcement, the company expects to submit marketing applications for DB-1303 (HER2 ADC) for endometrial cancer in the United States and for breast cancer in China in 2025. The company's DB-1311 (B7-H3 ADC) has shown potential best-in-class capabilities in prostate cancer, while DB-1310 (HER3 ADC) is expected to catch up from behind. DB-1305 (TROP2 ADC) and combination exploration with bispecific antibodies are leading globally, with autoimmune and bispecific ADCs continuously driving next-generation ADC frontier exploration.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}